Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial
Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial
Recruiting · NCT06976229 · Registry updated 2025-11-25Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial | central nervous system disorder, injury, nervous system disorder, nervous system injury, spinal cord disorder, spinal cord injury | Recruiting | Phase 1 | 2025-11-25 | NCT06976229 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Third Affiliated Hospital, Sun Yat-Sen University | 64 |
| XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 5 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Third Affiliated Hospital of Sun Yat-sen University | Guangzhou | China | 22 |